Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	228.00 ¥	-0.44%	40,400
17/06/26	229.00 ¥	+3.15%	37,500
16/06/26	222.00 ¥	-0.45%	29,700
15/06/26	223.00 ¥	+1.83%	14,900
12/06/26	219.00 ¥	+0.46%	7,200

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Market Closed - Japan Exchange Other stock markets 09:30:00 18/06/2026 +03			5-day change	1st Jan Change
228.00 ^JPY	-0.44%		+4.59%	-32.94%

06-17	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
06-01	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI

Market Cap	7.58B 47.33M 40.83M 37.54M 35.33M 66.39M 4.47B 66.95M 445M 173M 2.19B 178M 174M	P/E 2024	-14.1x	P/E 2025	49.7x
Enterprise Value	6.14B 38.29M 33.03M 30.37M 28.59M 53.72M 3.61B 54.17M 360M 140M 1.77B 144M 141M	EV / Sales 2024	10.8x	EV / Sales 2025	6.38x
Free-Float	27.85%	Yield 2024 *	-	Yield 2025	-

06-17	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
06-01	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
06-01	Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million.	CI
05-15	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
02-13	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
02-13	Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
12/05/25	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
17/02/25	Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
20/11/24	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
19/12/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	CI
20/09/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	CI
23/06/22	Tsubota Laboratory Incorporated has completed an IPO in the amount of Ã‘1.8048 billion.	CI
20/05/22	Tsubota Laboratory Incorporated has filed an IPO.	CI

1 day	-0.44%
1 week	+4.59%
Current month	-10.59%
1 month	-15.56%
3 months	-40.16%
6 months	-34.48%
Current year	-32.94%

Tsubota Laboratory Incorporated Stock

Stocks

4890

JP3535700003

Biotechnology & Medical Research

Valuation: Tsubota Laboratory Incorporated

Chart: Tsubota Laboratory Incorporated

Latest news : Tsubota Laboratory Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Tsubota Laboratory Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Kazuo Tsubota PSD	President	71	01/02/2019
Keisuke Mitsuoka ADM	Chief Administrative Officer	-	-
Kenji Morishima CTO	Chief Tech/Sci/R&D Officer	65	01/01/2025

Director	Title	Age	Since
Kazuo Tsubota BRD	Director/Board Member	71	01/02/2019
Shinichi Koizumi BRD	Director/Board Member	70	01/06/2020
Eri Kubota BRD	Director/Board Member	55	01/06/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/11/24	Kazuo Tsubota	Others	Founder	63,000	0.2465%
15/11/24	Kazuo Tsubota	Others	Founder	420,000	1.6434%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSUBOTA LABORATORY INCORPORATED	-0.44%	+4.59%	-42.57%	-67.84%	36.86M
LONZA GROUP AG	-0.99%	-0.79%	-12.78%	-11.09%	43.44B
REVOLUTION MEDICINES, INC.	+0.76%	+9.42%	+303.09%	+540.82%	33.54B
IQVIA HOLDINGS INC.	-4.74%	-6.31%	+10.75%	-20.99%	28.48B
BEONE MEDICINES AG	-0.47%	-0.35%	+3.38%	+31.20%	29.2B
CELLTRION, INC.	+0.06%	+4.36%	+13.31%	+21.11%	25.34B
ASCENDIS PHARMA A/S	-0.02%	+10.18%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-0.98%	-1.86%	+53.43%	+106.06%	13.05B
EUROFINS SCIENTIFIC SE	-0.93%	-3.67%	+2.45%	+3.30%	12.67B
IONIS PHARMACEUTICALS, INC.	+1.67%	+1.35%	+105.56%	+81.16%	12.28B
Average	-0.60%	+1.60%	+48.51%	+75.97%	21.24B
Weighted average by Cap.	-0.79%	+1.35%	+62.49%	+105.67%

	2024	2025
Net sales	673M 4.2M 3.62M 3.33M 3.14M 5.89M 396M 5.94M 39.48M 15.37M 195M 15.76M 15.43M	1.36B 8.47M 7.31M 6.72M 6.32M 11.88M 799M 11.98M 79.6M 30.99M 392M 31.79M 31.11M
Net income	-641M -4M -3.45M -3.17M -2.99M -5.61M -378M -5.66M -37.6M -14.64M -185M -15.01M -14.69M	205M 1.28M 1.1M 1.01M 955K 1.79M 121M 1.81M 12.03M 4.68M 59.26M 4.8M 4.7M
Net Debt	-1.77B -11.03M -9.51M -8.75M -8.23M -15.47M -1.04B -15.6M -104M -40.36M -511M -41.39M -40.51M	-1.45B -9.04M -7.8M -7.17M -6.75M -12.68M -853M -12.78M -84.94M -33.07M -419M -33.92M -33.19M

1 week	215	232
1 month	210	276
Current year	210	478
1 year	210	478
3 years	210	738
5 years	210	1,447
10 years	210	1,447